TAMPA, Fla., Dec. 01, 2016 -- After a week-long arbitration before a panel of three arbitrators, a local physician received a $1,500,000.00 award against healthcare giant OptumRx, a pharmacy benefits management company associated with United Healthcare. The award, which also required OptumRx to pay all costs associated with the litigation, included a finding that family medicine physician Jose I. Lopez, M.D. was entitled to punitive damages in the amount of $1,000,000.00 due to OptumRx’s “intentional misconduct or gross negligence” that was “condoned, ratified or consented to” by Optum’s officers, directors or managers.
Dr. Lopez was represented by Jody M. Valdes and Paul M. Weekley of Weekley Schulte Valdes in Tampa.
“More strikingly, however, the Panel of Arbitrators determined that OptumRx, Inc.’s wrongful conduct was ‘motivated solely by unreasonable financial gain and the unreasonably dangerous nature of the conduct, together with the high likelihood of injury resulting from the conduct, was actually known by the managing agent, director, officer, or other person responsible for making policy decisions,’” said Valdes.
“The case arose after OptumRx publicly and repeatedly made false statements about Dr. Lopez, wrongly labeling him as a physician-sanctioned by the Office of Inspector General. In actuality, OptumRx had misidentified Dr. Lopez. The Jose Lopez who was sanctioned by OIG lived in another city in Florida and was not even a physician. The Panel of Arbitrators concluded that OptumRx injured Dr. Lopez’s reputation in the community by falsely advising pharmacies, Dr. Lopez’s patients, and others that Dr. Lopez was a sanctioned provider. OptumRx failed to acknowledge the mistake and continued making the false statements despite repeated attempts by Dr. Lopez to get OptumRx to investigate whether OptumRx had identified another person with a similar name,” stated Weekley.
“We believe that this is the first case of its kind, in which a pharmacy benefits manager has been held accountable for poor procedures that resulted in a physician being wrongfully defamed,” stated Valdes. “During the litigation process, we learned that Dr. Lopez was one of many physicians who was defamed by similar misconduct or gross negligence,” added Weekley.
The Panel concluded that the “clear and unmistakable import of the false statements was that Claimants had engaged in some improper conduct sufficient to merit a “penalty, punitive or disciplinary action,” which is a definition of 'sanctioned',” said Valdes.
The Panel further noted that the “statements conveyed the false notion that Claimants had committed some offense in the medical profession sufficient to be disciplined and excluded as a Medicare provider – only leaving to the audience’s imagination which bad act, whether it be fraud, malpractice, etc., led to the punishment.” In reality, Dr. Lopez has always been in good standing with the state licensing agency, and with Medicare,” stated Weekley.
“The Panel determined that the evidence established to a clear and convincing standard that OptumRx, Inc. was aware of a problem with physicians being improperly listed as “sanctioned” and was specifically aware of this problem with Dr. Lopez. However, OptumRx, Inc. was unwilling to “take the few hours necessary to correct the information before publishing the information and did not engage in any efforts to correct its…continual misidentification,” said Valdes.
Dr. Lopez was pleased with the decision and commented that “this case was not about money. This case about sending a strong and clear message that faceless companies that libel and slander doctors must be held accountable for their actions.”
Eric W. Rose with Englander Knabe & Allen testified as an expert witness and addressed the effects of disseminating the false information and the impact on the doctor’s professional reputation. Rose also testified about the appropriate standard of care that should have taken place and outlined steps Dr. Lopez should take to recover his good professional reputation.
Contact: Paul M. Weekley, Esquire (813) 221-1154 or [email protected]


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



